|
|
Article: Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development.
- Article from:
- PR Newswire
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S. and will enroll approximately 1,120 subjects with ED.
Mr. Dong Hyun Park, President & CEO of Dong-A PharmTech, commented that, "We are extremely pleased to be entering the last ...
Related newspaper, magazine, and journal articles:
|
|
Article: Penetration sought in erectile dysfunction market.
M2 Presswire;
April 24, 2007 ;
700+ words
... ... DATAMONITOR: Penetration sought in erectile dysfunction market(C)1994-2007 M2 ... LondonWednesday April 25 2007-Erectile dysfunction (ED) is a serious urological ... preregistration to Phase III. Dong-A PharmTech Co., responsible for the ...
|
|